Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study

European Radiology

Volumn 25, Issue 9, 2015, Pages 2641-2650

  Miyazaki, Keiko ^a   Jerome, Neil P ^a   Collins, David J ^a   Orton, Matthew R ^a   d’Arcy, James A ^a   Wallace, Toni ^b   Moreno, Lucas ^a,c,d   Pearson, Andrew D J ^a,d   Marshall, Lynley V ^a,d   Carceller, Fernando ^a,d   Leach, Martin O ^a   Zacharoulis, Stergios ^a,d   Koh, Dow Mu ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Diffusion magnetic resonance imaging; Functional magnetic resonance imaging; Medical oncology; Paediatrics; Reproducibility of results

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; CONTRAST MEDIUM; GADOLINIUM;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCHOOL CHILD; SINGLE DRUG DOSE; SOLID TUMOR; BREATHING; COHORT ANALYSIS; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; NEOPLASMS; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; CHILD; COHORT STUDIES; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDIES; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; NEOPLASMS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; RESPIRATION; SENSITIVITY AND SPECIFICITY;

EID: 84938986601     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-015-3666-7     Document Type: Article

References (36)

1. Norris RE, Adamson PC (2012) Challenges and opportunities in childhood cancer drug development. Nat Rev Cancer 12:776–782
2. Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P et al (2013) New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol 14:e117–e124
3. Boklan J (2006) Little patients, losing patience: pediatric cancer drug development. Mol Cancer Ther 5:1905–1908
4. Chang Y-C, Yu C-J, Chen C-M, Hu F-C, Hsu H-H, Tseng W-YI et al (2012) Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging JMRI 36:387–396
5. Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES et al (2012) Changes in tumour blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory a. Gynecol Oncol 126:375–380
6. De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J et al (2012) Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 106:1926–1933
7. Desar IME, Ter Voert EGW, Hambrock T, Van Asten JJ, Van Spronsen DJ, Mulders PF et al (2011) Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging Off Publ Int Cancer Imaging Soc 11:259–265
8. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y et al (2012) Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumour effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 130:2359–2365
9. Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D et al (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neuro-Oncol 96:423–431
10. Koh D-M, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728–2738
11. Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR et al (2011) Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 47:997–1005
12. Messiou C, Orton M, Collins DJ, Morgan VA, Mears D, Ghiorghiu D et al (2012) Advanced solid tumours treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity 1. Radiology 265(2):426–36
13. Miyazaki K, Orton M, Davidson R (2012) Neuroendocrine tumour liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 263:139–148
14. O’Connor JPB, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F et al (2011) DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 105:139–145
15. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neuro-Oncol 108:491–498
16. Yoo DS, Kirkpatrick JP, Craciunescu O, Broadwater G, Peterson BL, Carroll MD et al (2012) Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18:1404–1414
17. Yopp A, Schwartz L, Kemeny N (2011) Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 18:2192–2199
18. Miyazaki K, D’Arcy JA, Orton MR, Koh D-M, Collins DJ, Leach MO (2011) Improved T1 quantification using post-Gd contrast variable flip angle data. International Society of Magnetic Resonance in Medicine. p 1092
19. De Bruin P, Versluis M, Yusuf E, Reignierse M, Watt I, Van Osch M (2010) Accuracy of T1-Fitting for Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI. International Society of Magnetic Resonance in Medicine. p 1720
20. Miyazaki K, Orton MR, Collins DJ, d’Arcy JA, Wallace T, Moreno L et al (2013) Preliminary analysis of arterial input function derived from dynamic contrast enhanced MRI in children with cancer. International Society of Magnetic Resonance in Medicine. p 720
21. Orton MR, Collins DJ, Messiou C, Castellano E, Tessier J, Spratt S et al (2010) A New Vascular Impulse Response Function for Modelling and Prediction with Measured Dynamic Contrast Enhanced Plasma Curves. International Society of Magnetic Resonance in Medicine. p 1726
22. Orton MR, d’Arcy JA, Walker-Samuel S, Hawkes DJ, Atkinson D, Collins DJ et al (2008) Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Phys Med Biol 53:1225–1239
23. Parker GJM, Roberts C, Macdonald A, Buonaccorsi G, Cheung S, Buckley DL et al (2006) Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med Off J Soc Magn Res Med/Soc Magn Reson Med 56:993–1000
24. Peet AC, Arvanitis TN, Leach MO, Waldman AD (2012) Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol 9:700–711
25. Jost SC, Ackerman JW, Garbow JR, Manwaring LP, Gutmann DH, McKinstry RC (2008) Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 38:1293–1299
26. Gahr N, Darge K, Hahn G, Kreher BW, Von Buiren M, Uhl M (2011) Diffusion-weighted MRI for differentiation of neuroblastoma and ganglioneuroblastoma/ganglioneuroma. Eur J Radiol 79:443–446
27. Rodriguez Gutierrez D, Manita M, Jaspan T, Dineen R, Grundy RG, Auer DP (2013) Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics. Neuro Oncol 15:981–989
28. Guo J, Reddick WE, Glass JO, Ji Q, Billups C, Wu J et al (2012) Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer 118:3776–3785
29. Navid F, Baker SD, McCarville MB, Stewart CF, Billups C, Wu J et al (2013) Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 19:236–246
30. Nathan P, Zweifel M, Padhani AR, Koh D-M, Ng M, Collins DJ et al (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18:3428–3439
31. Jamin Y, Tucker E, Poon E, Popov S (2013) Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiol 266:130–140
32. O’Connor JPB, Carano RAD, Clamp AR, Ross J, Ho CCK, Jackson A et al (2009) Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res Off J Am Assoc Cancer Res 15:6674–6682
33. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599–1610
34. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA et al (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 22:1451–1464
35. Quantitative Imaging Biomarkers Alliance. Profile: DCE MRI Quantification Version 1.6 (2011)
36. Wang Y, Huang W, Panicek DM, Schwartz LH, Koutcher JA (2008) Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med Off J Soc Magn Reson Med/Soc Magn Reson Med 59:1183–1189